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Summary
Background: In patients with paroxysmal atrial ﬁbrillation or ﬂutter (PAF/PAFL),
subjective symptoms are not concordant with real arrhythmic events. It is important
to elucidate the incidence of asymptomatic PAF/PAFL in symptomatic patients in a
clinical setting.
Methods and results: To identify a possible relationship with subjective symptoms,
we reviewed 6319 trans-telephonic electrocardiographic strips (ECGs) recorded
from 123 patients in a double-blind, placebo-controlled trial examining dose-
response effects of ﬂecainide. During a 4-week observation, 2848 ECGs, comprising
894 (31.4%) symptomatic and 1954 (68.6%) asymptomatic tracings, and, during
31 days of treatment, 3471 ECGs, comprising 874 (25.2%) symptomatic and 2587
(74.8%) asymptomatic tracings, were transmitted. There were signiﬁcantly fewer
symptomatic ECGs during the treatment period (Fisher’s exact test, P < 0.01).
Asymptomatic episodes accounted for 23.5% of the total in the observation period
and 22.4% of that in the treatment period (Fisher’s exact test, P = 0.561). But
the frequency of asymptomatic PAF/PAFL dropped signiﬁcantly, from 11.1% to
3.9% (P < 0.01), in the group receiving ﬂecainide 200mg/day. In the observation
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period, the positive predictive value of subjective symptoms was about 50%, and the
sensitivity in predicting PAF/PAFL, around 80%. During treatment, these values did
not change signiﬁcantly, but negative predictive value (NPV) and speciﬁcity increased
in the 200mg ﬂecainide group. In the analysis of each case, signiﬁcant dose-response
proﬁles were found in NPV (P = 0.019) and speciﬁcity (P = 0.041).
Conclusions: Asymptomatic PAF/PAFL was not rare in symptomatic patients, and ﬂe-
cainide reduced both symptomatic and asymptomatic episodes.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
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scrutinizing the individual ECG strip obtained.reserved.
ntroduction
trial ﬁbrillation (AF) is the most common arrhyth-
ia that requires medical treatment to prevent
ubstantial morbidity and mortality [1]. Paroxys-
al atrial ﬁbrillation or atrial ﬂutter (PAF/PAFL)
s usually recognized by typical symptoms such as
alpitation, chest discomfort caused by the sudden
nset of tachycardia, and irregular heart beat. In
he Framingham Heart Study [1], 40% of lone AF was
symptomatic, and in the Cardiovascular Health
tudy [2], the diagnoses in approximately one-third
f AF patients were made electrocardiographically
n the absence of any subjective symptom. In gen-
ral, the prevalence of asymptomatic lone AF has
een found in about 25% of the study patients in
rospective studies [3]. According to the AFFIRM
tudy, patients with asymptomatic AF had less
erious heart disease, but more frequent cere-
rovascular disease [4]. It is important to know the
linical characteristics of asymptomatic arrhyth-
ias in symptomatic patients not only as an aid in
he prevention of ischemic stroke associated with
AF/PAFL, but also for the management of patients
ith PAF/PAFL. Careful attention must therefore
e paid to asymptomatic arrhythmias because they
ay increase the risk of stroke. In the present study,
e reanalyzed the trans-telephonic ECGs in a mul-
icenter, placebo-controlled, double-blind trial of
ecainide [5] to elucidate the frequency of asymp-
omatic PAF/PAFL in symptomatic patients and also
valuated the effect of ﬂecainide on asymptomatic
AF/PAFL.
ethods
he relationship between ECG diagnosis and subjec-
ive symptoms on a total of 6319 trans-telephonic
CG strips recorded from 123 Japanese patients
ith a history of symptomatic PAF/PAFL was stud-ed. These patients were included in a multicenter,
lacebo-controlled, double-blind trial and random-
zed to placebo or ﬂecainide (25mg, 50mg, or
00mg) twice daily (BID) [5] so as to evaluate the
D
‘
wose-response preventive effect of ﬂecainide on
AF/PAFL. The test drugs and matching placebo
ere provided by Eisai Co., Ltd. (Tokyo, Japan).
he study protocol was approved by the Insti-
utional Review Board at each of 30 centers in
apan. This clinical trial consisted of a 4-week
bservation period and a 31-day treatment period.
uring the treatment period, 32 patients received
lacebo and 91 received ﬂecainide (26 patients
n 25mg, 32 on 50mg, and 33 on 100mg BID).
he present study represents the analysis for
he pre-speciﬁed (but not the primary) endpoint.
atients with a history of symptomatic PAF/PAFL
ho had experienced two or more attacks per
onth were eligible for participation in this study
5]. A trans-telephonic monitor with a memory
evice (Cardiophone, Nihon-Kohden, Tokyo, Japan)
as given to all participants who submitted writ-
en informed consent for this study. Patients were
nstructed how to record ECGs and were required to
ransmit routinely recorded ECGs for 30 s once a day
uring the study period, and also at any time they
ad a symptom that they felt indicated PAF/PAFL.
lso, if a patient had symptoms, ECG transmis-
ion was again required during the symptomatic
hase and immediately after disappearance of the
ymptoms. All ECGs were transmitted to the ECG
enter at Keio University Hospital and then for-
arded to each study center by facsimile to conﬁrm
he ECG diagnosis and to assess whether it was safe
o continue the study. Patients were also required
o record their subjective symptoms every day
hroughout the study period, whenever they were
ransmitting ECG records. Two cardiologists (HA,
O) reviewed and diagnosed all the ECGs without
ny information on subjective symptoms. We exam-
ned a possible association between ECG diagnoses
nd subjective symptoms related to PAF/PAFL byeﬁnitions
‘Symptomatic ECG’’ is deﬁned as an ECG recorded
hen a patient had any subjective symptom indica-
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tive of PAF/PAFL. This type of ECG implies true
PAF/PAFL, sinus rhythm, premature atrial complex
(PAC), and so on. ‘‘Asymptomatic ECG’’ is deﬁned
as an ECG recorded at a time when the patient had
no subjective symptoms. This was usually trans-
mitted as a routine daily ECG. ‘‘Asymptomatic
PAF/PAFL’’ is deﬁned as an ECG recorded when
PAF/PAFL was conﬁrmed without any subjective
symptom. Therefore, ‘‘asymptomatic PAF/PAFL’’
is included in ‘‘asymptomatic ECG.’’ Subjective
symptoms are classiﬁed into palpitation, chest dis-
comfort, chest pain, shortness of breath, dizziness,
and fatigue as PAF/PAFL-related symptoms.
Statistics
Data are expressed as mean± S.D. Demographic
and baseline characteristics of each group were
summarized using descriptive statistics. Continuous
variables and dose-response effects were analyzed
using one-way analysis of variance (ANOVA) and
categorical variables were analyzed using Fisher’s
exact test. Positive predictive value (PPV), negative
predictive value (NPV), sensitivity, and speciﬁcity
of symptoms to predict PAF/PAFL were calculated.
Changes in these indices with treatment in each
patient were averaged to test the statistical signif-
icance by paired-t-test. The dose-response effects
of ﬂecainide on these indices were tested with
ANOVA using contrast followed by Fisher’s least
square difference (LSD) method for inter-group
comparison (active versus placebo).
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Table 1 Baseline clinical characteristics of the study patie
Placebo (n = 32) 25mg BID (n
Men (%) 28 (87.5) 22 (84.6)
Age (years) 59.4± 10.2 61.8± 9.8
Weight (kg) 67.5± 13.5 64.5± 9.5
Arrhythmia
PAF 27 (84.4) 16 (61.5)
PAF and PAFL 5 (15.6) 10 (38.5)
History of PAF/PAFL (years) 4.1± 4.5 4.3± 5.8
Underlying disease
Total (%) 24 (75.0) 21 (80.8)
Valvular disease 3 (9.4) 3 (11.5)
Cardiomyopathy 2 (6.3) 0 (0.0)
Angina pectoris 0 (0.0) 1 (3.8)
Hypertension 16 (50.0) 7 (26.9)
Pre-excitation syndrome 1 (3.1) 0 (0.0)
BID, twice daily; PAF, paroxysmal atrial ﬁbrillation; PAFL, paroxys
one-way ANOVA (for continuous variables) and Fisher’s exact test (
from Atarashi et al. [5]).H. Atarashi et al.
esults
he clinical characteristics of the patients studied
re shown in Table 1. A total of 2848 ECGs com-
rising 894 (31.4%) symptomatic and 1954 (68.6%)
symptomatic episodes were transmitted during a
-week observation period, and 3471 ECGs com-
rising 874 (25.2%) symptomatic and 2597 (74.8%)
symptomatic episodes were transmitted during
he 31-day treatment period. The frequency of
ymptomatic ECGs was signiﬁcantly decreased dur-
ng the treatment period (Fisher’s exact test,
< 0.01).
A total of 4442 ECG records showed sinus
hythm; 1176, atrial ﬁbrillation (AF)/atrial ﬂutter
AFL); 600, atrial premature complex (APC); 74,
entricular premature complex (VPC); 37, sinus
achycardia. During the observation period, 626
22.0%) ECGs showed PAF/PAFL; 339 (11.9%), APC;
3 (1.5%), VPC; 22 (0.8%), sinus tachycardia (ST);
he remaining 1823 (64.0%) ECGs demonstrated a
ormal sinus rhythm. During the 31-day treatment
eriod, there were 550 (15.8%) AF/AFL cases, 261
7.5%) APC, 31 (0.9%) VPC, 14 (0.4%) sinus tachycar-
ia, and the remaining 2619 (75.5%) were normal
inus rhythm cases.
ubjective symptoms associated with
ymptomatic ECG
he frequency of subjective symptoms at the time
f the ECG recording was decreased, and con-
nts
= 26) 50mg BID (n = 32) 100mg BID (n = 33) P-value
23 (71.9) 24 (72.7) 0.311
57.7± 10.2 57.6± 11.0 0.393
66.3± 12.3 63.2± 8.9 0.449
25 (78.1) 27 (81.8)
0.1737 (21.9) 6 (18.2)
4.0± 3.8 6.0± 6.2 0.377
23 (71.9) 28 (84.8) 0.604
2 (6.3) 0 (0.0)
1 (3.1) 0 (0.0)
0 (0.0) 1 (3.0)
11 (34.4) 13 (39.4)
0 (0.0) 0 (0.0)
mal atrial ﬂutter. Data are mean± S.D. P-value is based on
for categorical variables) (reprinted in part, with permission,
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Figure 1 Dose-dependent effect of ﬂecainide on frequency of subjective symptoms (ECG-related). The open bars
a ing t
r Fish
v
ﬂ
(
a
o
t
f
i
n
T
t
q
d
a
h
t
o
e
o
m
w
i
o
i
t
1
P
6
a
C
P
T
E
T
F
ﬂ
pnd striped bars indicate the frequency of symptoms dur
espectively. *P < 0.05, **P < 0.01 (vs. observation period:
ersely, asymptomatic ECGs were increased after
ecainide treatment in a dose-dependent manner
Fig. 1). The frequency of asymptomatic ECGs was
round 70% in each treatment group during the
bservation period.
The most frequent subjective symptom related
o PAF/PAFL was palpitation, and the second most
requent was chest discomfort. Other symptoms,
ncluding chest pain, shortness of breath, dizzi-
ess and fatigue, were relatively less frequent.
he subjective symptoms when the ECG showed
rue PAF/PAFL are summarized in Fig. 2. The fre-
uency of these subjective symptoms appeared to
ecrease dose-dependently, and the frequency of
symptomatic ECGs (asymptomatic PAF/PAFL) was
igher (over 30% of total recorded PAF/PAFL) in
he 100mg BID group than in other groups in both
bservation and treatment periods (Fig. 2). How-
ver, there was no signiﬁcant difference between
bservation and treatment periods in any treat-
ent group or in the treatment groups as a
hole.
n
o
o
b
(
igure 2 Dose-dependent effect of ﬂecainide on frequency
utter documented by ECG. The open bars and striped bars ind
eriod and the treatment period, respectively. *P < 0.05 (vs. ohe observation period and during the treatment period,
er’s exact test).
In PAF/PAFL episodes, 147 of 626 ECG record-
ngs (23.5%) were found to be asymptomatic in the
bservation period; while 123 of 550 ECG record-
ngs (22.4%) were found to be asymptomatic in
he treatment period (NS). But in the ﬂecainide
00mg BID group, the frequency of asymptomatic
AF/PAFL decreased signiﬁcantly from 11.1% (69 of
19 recorded as asymptomatic) to 3.9% (37 of 959,
s above) (P < 0.01) (Fig. 3).
orrelation of subjective symptoms and
AF/PAFL
he associations of subjective symptoms with
CG-recorded PAF/PAFL are summarized in
ables 2 and 3. Flecainide therapy did not sig-
iﬁcantly affect PPV or sensitivity. In both the
bservation and the treatment periods, the PPV
f subjective symptoms was about 50%, and
oth sensitivity and speciﬁcity were around 80%
Table 2). In by-patient analysis (Table 3), PPV
of subjective symptoms during episodes of PAF/PAFL or
icate the frequency of symptoms during the observation
bservation period: Fisher’s exact test).
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Figure 3 Effect of ﬂecainide on frequency of asymp-
tomatic PAF/PAFL in ECG recorded in an asymptomatic
state. The open bars and striped bars indicate the fre-
quency of asymptomatic episodes during the observation
D
T
i
o
m
T
i
(
s
v
w
i
a
T
t
s
t
D
T
t
w
dperiod and the treatment period, respectively. **P < 0.01
(vs. observation period: Fisher’s LSD).
and sensitivity did not demonstrate signiﬁcant
differences between the observation and treat-
ment periods. In the 100mg BID group, the PPV
decreased from 74.1% to 63.3% in the treatment
period, but there was no signiﬁcant difference, but
NPV and speciﬁcity were signiﬁcantly increased:
from 87.5% to 95.2% (P = 0.016) and from 86.1% to
91.3% (P = 0.050), respectively. There were also
signiﬁcant dose-responses seen in NPV (P = 0.019)
and in speciﬁcity (P = 0.041).
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Table 2 Effect of ﬂecainide on correlation of subjective sy
Dose O
PPV Placebo 4
25mg BID 5
50mg BID 5
100mg BID 5
NPV Placebo 9
25mg BID 9
50mg BID 9
100mg BID 8
Sensitivity Placebo 9
25mg BID 8
50mg BID 7
100mg BID 6
Speciﬁcity Placebo 8
25mg BID 7
50mg BID 8
100mg BID 8
PAF, paroxysmal atrial ﬁbrillation; PAFL, paroxysmal atrial ﬂutter; P
BID, twice daily.H. Atarashi et al.
iagnosis of symptomatic ECGs
he ECGs made when the patients reported feel-
ng subjective symptoms related to PAF/PAFL and
btained in the observation period and in the treat-
ent period numbered 894 and 874, respectively.
he ECG revealed PAF/PAFL in 479 (53.6%), PAC
n 154 (17.2%), premature ventricular contraction
PVC) in 22 (2.5%), and ST in 9 (1.0%). The other
ubjects all had normal sinus rhythms in the obser-
ation period. In the treatment period, PAF/PAFL
as seen in 427 (48.9%), APC in 154 (17.6%), PVC
n 13 (1.5%), and ST in 9 (1.0%). The distribution of
rrhythmias in the 4 study groups is summarized in
able 4. The frequency of PAC was decreased while
hat of normal sinus rhythm was increased, both
igniﬁcantly (P < 0.01), in the treatment period at
he maximum dose of 100mg BID.
iscussion
he key ﬁndings of this study are that asymp-
omatic PAF/PAFL is not rare in PAF/PAFL patients
ho report no symptoms, and that PAF/PAFL is
ecreased in frequency with ﬂecainide treatment.ffect of an antiarrhythmic drug on
symptomatic PAF/PAFL
lecainide treatment contributes to decreasing the
requency of real symptomatic PAF/PAFL. Sup-
mptoms and PAF/PAFL (analysis by each ECG)
bservation period Treatment period
9.1% (108/220) 51.2% (144/281)
4.6% (124/227) 37.6% (97/258)
7.8% (130/225) 61.1% (113/185)
2.7% (117/222) 48.7% (73/150)
7.5% (469/481) 96.5% (531/550)
2.3% (371/402) 93.5% (505/540)
2.3% (417/452) 94.2% (516/548)
8.9% (550/619) 96.1% (922/959)
0.0% (108/120) 88.3% (144/163)
0.0% (124/155) 73.5% (97/132)
8.8% (130/165) 77.9% (113/145)
2.9% (117/186) 66.4% (73/110)
0.7% (469/581) 79.5% (531/668)
8.3% (371/474) 75.8% (505/666)
1.4% (417/512) 87.8% (516/588)
4.0% (550/655) 92.3% (922/999)
PV, positive predictive value; NPV, negative predictive value;
Asym
ptom
atic
paroxysm
alatrialﬁbrillation/ﬂ
utter
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Table 3 Effect of ﬂecainide on correlation of subjective symptom and PAF/PAFL (analysis by subject)
Dose Observation period Treatment period  (treatment− observation) P-value
N Mean± S.D. N Mean± S.D. N Mean± S.D. Observation vs.
Treatmenta
vs. placebob Dose-responsec
PPV Placebo 32 65.7 ± 29.7 31 67.9 ± 31.9 31 2.2 ± 27.7 0.659 — 0.867
25mg BID 26 67.6 ± 25.7 26 58.5 ± 35.2 26 −9.1 ± 29.3 0.125 0.161
50mg BID 32 72.6 ± 30.2 29 71.8 ± 30.3 29 −0.2 ± 24.0 0.958 0.754
100mg BID 33 74.1 ± 30.1 27 63.3 ± 37.8 27 −9.7 ± 38.8 0.208 0.139
NPV Placebo 32 96.8 ± 5.4 31 96.4 ± 5.7 31 −0.3 ± 6.5 0.789 — 0.019
25mg BID 26 89.5 ± 13.4 26 91.6 ± 14.9 26 2.2 ± 9.4 0.249 0.515
50mg BID 32 93.7 ± 11.3 32 91.5 ± 16.5 32 −2.2 ± 18.9 0.520 0.608
100mg BID 33 87.5 ± 23.8 33 95.2 ± 11.5 33 7.7 ± 17.4 0.016 0.027
Sensitivity Placebo 32 92.2 ± 14.5 32 89.9 ± 20.2 32 −2.3 ± 26.8 0.630 — 0.675
25mg BID 26 84.1 ± 17.4 24 85.3 ± 23.6 24 1.1 ± 20.8 0.791 0.633
50mg BID 32 87.1 ± 22.1 29 82.1 ± 23.4 29 −3.6 ± 22.2 0.386 0.847
100mg BID 33 79.9 ± 25.6 27 73.1 ± 35.1 27 −4.0 ± 34.4 0.551 0.808
Speciﬁcity Placebo 32 83.7 ± 17.6 32 81.0 ± 25.2 32 −2.7 ± 21.6 0.480 — 0.041
25mg BID 26 81.1 ± 19.0 26 79.8 ± 22.8 26 −1.3 ± 21.8 0.763 0.777
50mg BID 32 86.0 ± 17.4 32 87.0 ± 20.0 32 1.1 ± 18.0 0.738 0.425
100mg BID 32 86.1 ± 16.9 33 91.3 ± 15.5 32 5.1 ± 14.2 0.050 0.101
PAF, paroxysmal atrial ﬁbrillation; PAFL, paroxysmal atrial ﬂutter; PPV, positive predictive value; NPV, negative predictive value; BID, twice daily.
a Paired-t-test.
b Fisher’s LSD for inter-group comparison (active vs. placebo).
c ANOVA using contrast.
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PH. Atarashi et al.
ression of symptoms may be associated with
limination of arrhythmias or with a conversion
rom symptomatic to asymptomatic arrhythmias.
n general, antiarrhythmic drugs reduce the ven-
ricular rate in PAF/PAFL [6—8] may contribute to
conversion from symptomatic to asymptomatic.
symptomatic PAF increased after pulmonary vein
solation also [9,10], and this may be attributed
o digitalis therapy [4,11]. Conversion of arrhyth-
ias from symptomatic to asymptomatic seems to
e associated with a decrease in the duration of
rrhythmia or to a slowing of the heart rate, or
o both [3,4,11]. On the other hand, Page and
olleagues [12] reported that asymptomatic PAF
ccurred 12 times as often as sustained symp-
omatic PAF, and the mean heart rates did not
iffer much between the two groups. Strickberger
t al. [13] also reported that there was no sig-
iﬁcant difference in ventricular rate between
he symptomatic and asymptomatic arrhythmic
vents. The question of whether the ventricu-
ar rate affected the subjective symptoms during
AF was still a matter of controversy. Although
ral ﬂecainide therapy reduces heart rate during
PAF episode, the effect of ﬂecainide on asymp-
omatic PAF [6] is not reported in these studies.
owever, the present study indicated that the fre-
uency of asymptomatic PAF/PAFL was signiﬁcantly
ecreased after 100mg BID ﬂecainide therapy.
n patients with PAF/PAFL, a strong correlation
as noted between symptoms and documented
AF/PAFL [6]. A sensitivity of 89% for symptomatic
AF, as well as a speciﬁcity of 70%, a PPV of
9%, and an NPV of 89% were found in the pre-
ious double-blind trial of ﬂecainide [6]. In that
rial, patients received placebo or 200—300mg/day
f ﬂecainide, and PAF was recorded in 62.9%
f all symptomatic ECGs but in only 10.6% of
symptomatic ECGs. These results were equiva-
ent to our own ﬁndings. In the present study,
he percentage of asymptomatic PAF/PAFL in the
00mg BID group was 11.9% in the observation
eriod, a value that was decreased by 3.9% in
he treatment period, and this clinical effect was
ccompanied by a signiﬁcant dose dependency of
PV and of speciﬁcity in the analysis of each
ase. Our results clearly indicated that ﬂecainide
uppressed not only symptomatic but also asymp-
omatic PAF/PAFL. These ﬁndings may reﬂect the
linical effect of ﬂecainide. It was also reported
hat azimilide [14], a class III antiarrhythmic
rug, reduced asymptomatic PAF using by trans-
elephonic ECG. The clinical effects of antiarrhyth-
ic drugs such as ﬂecainide appear to decrease
ot only symptomatic but also asymptomatic
AF/PAFL.
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Rsymptomatic paroxysmal atrial ﬁbrillation/ﬂutter
AF/PAFL-related subjective symptoms
n the present study, palpitation and chest discom-
ort were the most common subjective symptoms
ndicative of PAF/PAFL. In general, PAF develops
uddenly and induces severe subjective symptoms,
specially in the ﬁrst episode; however, these sub-
ective symptoms often become less noticeable
o patients themselves despite the recurrence or
xtended duration of the disease, or both. There-
ore, an asymptomatic episode of PAF/PAFL is not
are even in symptomatic patients. In the present
tudy, we classiﬁed subjective symptoms into pal-
itation, chest discomfort, chest pain, shortness
f breath, dizziness, and fatigue in order to com-
are the speciﬁcity of each subjective symptom
f PAF/PAFL. Palpitation, chest pain, tachycardia,
hortness of breath, and dizziness [15,16] were
ommon as PAF-associated subjective symptoms in
aucasian as well as Japanese patients. Dizziness
ppears to be less frequent in Japanese patients,
ut there was no signiﬁcant ethnicity regarding any
ubjective symptom related to PAF.
iagnosis of symptomatic ECG
n the present study, in symptomatic ECG, i.e.,
he ECG recorded when a patient’s symptoms are
ndicative of PAF/PAFL, PAC was the most com-
on arrhythmia, but a normal sinus rhythm with
heart rate below 100/min was more frequent.
hese results were different from our predictions.
uring the treatment period, this tendency did
ot change. Only at the highest ﬂecainide dose of
00mg BID was the frequency of PAC signiﬁcantly
ecreased (P < 0.01), resulting in an increase in the
requency of the normal sinus rhythm. These results
uggest that ﬂecainide actually suppresses PAC fre-
uency, but rather increases the frequency of false
ositive trans-telephonic ECGs.
linical implications
n patients with PAF/PAFL, the reduction of symp-
oms reported above is probably attributable
o better control of heart rate and regularity
f ventricular responses, resulting in a greater
mprovement in the quality of life. But the risk of
omplications such as stroke probably does not dif-
er between symptomatic and asymptomatic PAF
ecause of the continuous advancement of elec-
rical and mechanical remodeling of the atria.
ven when PAF/PAFL patients become completely109
symptomatic after being prescribed an antiar-
hythmic drug, it is difﬁcult to conﬁrm whether they
ave or have not had an arrhythmic event. There-
ore, PAF/PAFL patients with a risk of stroke should
ot discontinue anticoagulation therapy [17].
imitations of the study
n the present study, all patients were required to
ransmit ECG recordings only for 30 s routinely once
day, and also at any time when they had symp-
oms indicative of PAF/PAFL, and again immediately
fter the symptoms disappeared. Therefore, dif-
ering numbers of transmitted ECGs were observed
n each treatment group, and the duration of the
bservation period and the treatment periods were
lso not the same. The correlation between subjec-
ive symptoms and PAF/PAFL was analyzed based
n the mean number of episodes in each case. A
lowing of the heart rate during PAF/PAFL may have
aused arrhythmic episodes to be asymptomatic;
owever, the heart rate per ECG recording was not
nvestigated in this study.
onclusions
espite the limited amount of data obtained in the
resent study, the results indicate that ﬂecainide
as beneﬁcial effects not only on symptomatic but
n asymptomatic episodes.
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